Ask AI
ProCE Banner Activity

Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies

Podcast Episodes

In this episode, 2 experts discuss how immunotherapy has reshaped the treatment landscape of acute lymphoblastic leukemia (ALL), highlighting advances in bispecific antibodies, CAR T-cell therapies, and MRD-guided strategies in both frontline and relapsed/refractory settings. They also explore evolving decisions around toxicity, treatment sequencing, transplant, and the promise of more effective, less burdensome approaches that may further improve long-term outcomes.

Released: March 02, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This educational activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with ALL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply increased knowledge of clinical and molecular features that influence the selection and sequencing of immune-targeted therapies in acute lymphoblastic leukemia (ALL)

  • Integrate emerging evidence from clinical trials, recent approvals, and updated guideline recommendations for bispecific T-cell engagers and CAR T-cell therapies into the management of patients with ALL

  • Develop evidence-based strategies to proactively recognize and manage adverse events associated with immune-targeted agents, supporting early intervention and sustained patient benefit in ALL care

Disclosure

Primary Author

Ibrahim Aldoss, MD, has no relevant financial relationships to disclose.

Bijal D. Shah, MD, MS: consultant/advisor/speaker: ADC Therapeutics, Amgen, AstraZeneca, Autolus, BeiGene, Bristol Myers Squibb, Deciphera, Jazz, Kite/Gilead, Lilly, Novartis, Pfizer, Precision Biosciences, Servier, Syndax, Takeda; steering committee: Amgen, AstraZeneca; independent data monitoring committee: Amgen, BeiGene, Novartis, PeproMene Bio; researcher: Jazz, Kite/Gilead, Servier.